Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

Neurology

Volumn 49, Issue 2, 1997, Pages 358-363

  Rudick, R A ^a   Goodkin, D E ^b   Jacobs, L D ^c   Cookfair, D L ^c   Herndon, R M ^d   Richert, J R ^e   Salazar, A M ^f   Fischer, J S ^a   Granger, C V ^c   Simon, J H ^g   Alam, J J ^h   Simonian, N A ^h   Campion, M K ^h   Bartoszak, D M ^f   Bourdette, D N ⁱ   Braiman, J ^f   Brownscheidle, C M ^c   Coats, M E ^f   Cohan, S L ^e   Dougherty, D S ^k   Kinkel, R P ^a   Mass, M K ^d   Munschauer, F E ^c   Priore, R L ^c   Pullicino, P M ^c   Scherokman, B J ^j   Weistock Guttman, B ^a   Whitham, R H ⁱ   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BIOGEN   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j KAISER PERMANENTE   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 8544249096     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.358     Document Type: Article

References (14)

1. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
2. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular rccombinant beta Interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis 1995;1:118-135.
3. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Arch Neurol 1992;42: 859-863.
4. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994;36 (suppl 1): S108-S112.
5. Jacobs L, Munschauer F. Treatment of multiple sclerosis with interferons. In: Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis: trial design, results and future perspectives. London: Springer-Verlag, 1992:233-250.
6. The IFNB Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
8. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
9. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114: 1045-1056.
10. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
11. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
12. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment, and future perspectives. London: Springer-Verlag, 1996:223-250.
13. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
14. Cookfair DL, Fischer J, Rudick R, et al. Quality of life in low-disability multiple sclerosis patients participating in a phase III trial of interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1996;40:550.